SCHEMBL1641845

SCHEMBL1641845

O=C(O)CNC(=O)c1c(O)c(C(=O)NC2CCCCC2)c(O)n(C2CCCCC2)c1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 11/20 0.67
EGLN3 Q9H6Z9 2/20 0.67
HIF1AN Q9NWT6 2/20 0.67
OGFOD1 Q8N543 1/20 0.67
EGLN2 Q96KS0 1/20 0.67
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
GAA P10253 1/20 0.42
PPARG P37231 1/20 0.42
NCOA2 Q15596 1/20 0.42
BBOX1 O75936 2/20 0.40
ASPH Q12797 2/20 0.40
KDM8 Q8N371 2/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
XBP1 P17861 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642217 1.00 EGLN1 (0.67) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1641949 1.00 EGLN1 (0.67) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1640799 0.99 EGLN1 (0.66) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1641147 0.99 EGLN1 (0.66) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1641734 0.93 EGLN1 (0.77) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1641888 0.87 EGLN1 (0.69) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1640290 0.87 EGLN1 (0.65) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1642740 0.87 EGLN1 (0.65) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1641194 0.86 EGLN1 (0.67) EGLN1EGLN3HIF1ANOGFOD1EGLN2
SCHEMBL1640775 0.86 EGLN1 (0.64) EGLN1EGLN3HIF1ANOGFOD1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US claimed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP claimed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO claimed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN1 6/4885EGLN3 3/4885HIF1AN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.